Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study
Table 2
Efficacy results at week 48 before PSM.
Responses
PegIFNα + NSs (n = 18)
PegIFNα + NTs (n = 77)
(total)
(ETV vs. ADV)
(ETV vs. TDF)
(ADV vs. TDF)
PegIFNα + ETV (n = 18)
PegIFNα + ADV (n = 40)
PegIFNα + TDF (n = 37)
HBsAg reduction from baseline at week 48, log10 IU/mL
–2.33
–3.45
0.040
–2.33
–3.47
–3.44
0.082
0.029
0.046
0.901
HBeAg reduction from baseline at week 48, s/co
–394.33
–532.37
0.447
–394.33
–654.90
–409.83
0.167
0.175
0.937
0.091
HBV DNA reduction from baseline at week 48, log10 IU/mL
–3.32
–4.57
0.198
–3.32
–5.02
–4.10
0.251
0.112
0.481
0.287
HBsAg loss, n (%)
4 (22.2)
5 (6.5)
0.109
4 (22.2)
2 (5.0)
3 (8.1)
0.152
0.068
0.200
0.667
HBeAg loss, n (%)
3 (23.1)
11 (16.9)
0.895
3 (23.1)
7(21.2)
4 (12.5)
0.562
1.000
0.394
0.349
HBeAg seroconversion, n (%)
2 (15.4)
8 (12.3)
1.000
2 (15.4)
5 (15.2)
3 (9.4)
0.742
1.000
0.617
0.708
HBV DNA undetectable, n (%)
17 (94.4)
72 (94.7)
1.000
17 (94.4)
35 (89.7)
37 (100)
0.062
1.000
0.327
0.116
HBsAg reduction >1 log10 from baseline, n (%)
13 (72.2)
76 (98.7)
0.001
13 (72.2)
40 (100)
36 (97.3)
0.004
0.026
0.035
0.481
HBsAg reduction >1 log10 and DNA undetectable, n (%)
